HQL earnings date and last-quarter result: P/E 2.92. Updated 2026-07-23.
Tekla Life Sciences Investors (HQL) Research Hub
Tekla Life Sciences Investors (HQL) trades on NYSE, US in the Financial Services (Asset Management) sector. As of 2026-10-26, shares last closed at 17.7 USD (-0.17%), in a range — insufficient history for 200-DMA. Valuation: trailing P/E 2.92, market cap 0.60B. This hub links to the full technical, earnings and options research available for HQL.
Last updated 2026-10-26 · Source: end-of-day prices (adjusted); indicators computed by SniperIQ
| Sector | Financial Services (Asset Management) |
|---|---|
| Exchange | NYSE, US |
| Last close | 17.7 USD (-0.17%) |
| 52-week range | 16.53 USD – 22.67 USD |
| Trend regime | Range |
| 14-day RSI | 51.8 (Neutral) |
| Trailing P/E | 2.92 |
| Market cap | 0.60B |
| Dividend yield | 10.35% |
Available research for HQL
Covered Call on HQL: how it works, illustrative setup around the real 17.7 USD price, max profit/loss, breakeven and when to use it. Educational.
Iron Condor on HQL: how it works, illustrative setup around the real 17.7 USD price, max profit/loss, breakeven and when to use it. Educational.
Protective Put on HQL: how it works, illustrative setup around the real 17.7 USD price, max profit/loss, breakeven and when to use it. Educational.
HQL technical analysis: range, last 17.7 USD, RSI 51.8, 52w range 16.53 USD–22.67 USD, real support/resistance. Updated 2026-10-26.
More on SniperIQ
Frequently asked questions
What sector is HQL in?
Tekla Life Sciences Investors (HQL) is classified under Financial Services (Asset Management), listed on NYSE, US.
Is HQL in an uptrend or downtrend?
As of 2026-10-26, HQL is in a range — insufficient history for 200-DMA. See the full technical research page for support and resistance levels.
What is HQL's trailing P/E ratio?
HQL's trailing P/E is 2.92, with a market cap of 0.60B. See the earnings research page for full valuation detail.